Tag
Lorundrostat, an aldosterone synthase inhibitor, significantly reduced systolic blood pressure in adults with uncontrolled and treatment-resistant hypertension, demonstrating efficacy and safety as an adjunct therapy.
Weekly fixed-dose insulin efsitora demonstrated noninferiority to daily glargine in reducing HbA1c in insulin-naïve type 2 diabetes, with fewer hypoglycemic events and simpler dose adjustment.
Recent randomized trials show ashwagandha, including Somin-On™, significantly improves memory and cognitive function in adults with mild cognitive impairment and healthy young adults, with good safety profiles.
A double-blind RCT suggests pomegranate peel extract may improve liver enzymes, lipid profile, and inflammation in NAFLD patients, but does not significantly alter liver steatosis grade.
Flaxseed powder supplementation shows promise in improving liver fat, lipid metabolism, and inflammation in NAFLD and related metabolic disorders, with effects on gut microbiota but limited synergism with fasting mimicking diets.
A 12-week hypocaloric Mediterranean diet with early time-restricted feeding improved glycaemic control and cardiometabolic risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) compared to unrestricted timin
This clinical trial compared two modified intermittent fasting strategies to continuous energy restriction for weight loss and insulin resistance improvements in night shift workers, finding no significant differences but overall health ben
A recent RCT suggests intermittent fasting may improve physical function and disease activity in overweight and obese postmenopausal women with RA, but shows no significant effect on inflammation or oxidative stress markers.
Recent clinical trials reveal the therapeutic potential of Akkermansia muciniphila strains in alleviating respiratory symptoms, improving muscle strength, and preventing diet-induced obesity in dogs.
A phase II trial finds that intrathecal autologous bone marrow mononuclear cell therapy combined with education significantly improves core symptoms and adaptive behaviors in young children with ASD compared to education alone.
The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.
A phase 2 trial shows that olverembatinib combined with venetoclax and reduced-intensity chemotherapy achieves high molecular response and survival rates in newly diagnosed Ph+ ALL patients, offering a less intensive alternative.
The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.
A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.
The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.
A multimodal intervention significantly improved sexual satisfaction in hematopoietic stem-cell transplantation (HSCT) survivors compared to enhanced usual care, highlighting a promising approach for addressing sexual dysfunction in this po
Testosterone therapy offers modest benefits for sexual function, anemia, and bone health in older men with hypogonadism, but increases risks of venous thromboembolism, fractures, and arrhythmias. Careful patient selection and individualized
The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and
Semaglutide significantly improved glycemic control and weight loss in adults with type 1 diabetes and obesity, without increasing major safety risks, according to the ADJUST-T1D trial.
Trehalose was safe but did not slow ALS progression compared to placebo in a large, adaptive phase 2/3 trial.
